Pfizer's Q1 Performance Beats Estimates; UBS Maintains Neutral Rating

Overview

This report is a commentary by UBS on Pfizer’s Q1 2026 earnings. Pfizer’s Q1 revenue and profit both exceeded market consensus, primarily driven by the strong performance of legacy products like Eliquis and Ibrance, as well as growth products such as Nurtec and Padcev. However, the COVID-19 vaccine Comirnaty fell significantly short of expectations. The company has maintained its 2026 financial guidance and expressed greater confidence in its long-term revenue outlook post-2029, largely due to the Tafamidis settlement which extends the exclusive sales period for Vyndamax until 2031. UBS maintains a neutral rating and a target price of $27, noting that there remains significant uncertainty regarding whether the pipeline can fill the expected gap from over $150 billion in patent expirations after 2029.

Core views

Performance: Pfizer's Q1 total revenue reached $144.51B, surpassing the market consensus of $138.4B, representing a 5.4% year-over-year increase. Core products such as Eliquis ($22B vs. $19B consensus) and Ibrance ($10B vs. $9.14B consensus) outperformed expectations, with growth products like Nurtec, Padcev, and Lorbrena also making substantial contributions. The COVID-19 vaccine Comirnaty generated only $2.32B, far below the $4.37B consensus, although UBS notes this was anticipated. Guidance & Long-Term Outlook: The company reiterated its 2026 financial guidance, projecting revenues between $595-$625B and adjusted diluted EPS between $2.80-$3.00. Management updated their outlook to anticipate a five-year period starting in 2029 with high-single-digit annual revenue growth, supported by the Tafamidis settlement which delays the loss of exclusivity for Vyndamax from late 2028/early 2029 to 2031. Key Disagreement: UBS believes the market still undervalues this long-term growth expectation, remaining essentially neutral. This caution arises because Pfizer faces an LOE (loss of exclusivity) shortfall exceeding $150B across various business lines, with considerable uncertainty around which pipeline assets will bridge this gap—a 'to be determined' status for investors. Upcoming Catalysts: Key near-term catalysts identified by UBS include data readouts from Sèv B6A ADC in second-line non-small cell lung cancer, obesity data from MTSR (including complete VESPER-3 study data on monthly GLP-1 regimens and combined GLP-1 and amylin data), mid-to-late-year EZH2 prostate cancer III trial data, and insights from ASCO presentations regarding PD-1×VEGF competitors’ impact on Pfizer’s III-phase projects.

Analysis framework

UBS analysis focuses on two main aspects: validating short-term performance and evaluating medium-term revenue sustainability. For short-term validation, individual product Q1 actual revenues are compared against UBS forecasts and market consensus to assess the resilience and growth drivers of Pfizer’s portfolio. Medium-term evaluation centers on LOE (loss of exclusivity) gap analysis, assessing structural pressures on future revenues—specifically, Pfizer’s exposure to over $150B in LOE risk. A critical determinant is identifying which pipeline assets can bridge this gap. The Tafamidis settlement, delaying Vyndamax’s LOE from the end of 2028 to 2031, directly enhances visibility into post-2029 revenue, forming the core rationale behind UBS’s improved long-term confidence. Valuation-wise, UBS employs a one-year forward P/E approach, backed by DCF (discounted cash flow) analysis for support. By comparing forecast stock return (FSR = expected price appreciation + total dividend yield) with a market return assumption (MRA = one-year local currency market rate + 5%), UBS defines rating tiers. Currently, FSR stands at 9.2%, MRA at 8.9%, placing Pfizer within the neutral range.

Methodology notes

• Valuation MethodPE/PEG valuation

  One-Year Forward P/E Approach

  This method calculates the price-to-earnings ratio based on expected EPS for the next 12 months to set a target price. UBS uses it as the primary basis for Pfizer’s target price and supports it with DCF modeling, typical for mature pharmaceutical companies.

• Valuation MethodDCF Discounted Cash Flow

  DCF Support for Valuation

  This technique discounts projected future cash flows to present value to estimate intrinsic worth. In this context, it serves as a secondary check on the reasonableness of the P/E-derived target price.

• Industry/Industrial Analysis Framework

  LOE (Loss of Exclusivity) Gap Analysis

  LOE signifies the loss of patents or exclusive rights, allowing generics to enter and erode original drug revenues. Assessing future revenue sustainability hinges on determining existing product gaps and whether R&D pipelines can cover them. With Pfizer facing over $150B in LOE risk, this assessment is central to evaluating long-term prospects.

• Corporate Fundamentals and Financial Framework

  Predicted Stock Return (FSR) vs Market Return Assumption (MRA) Rating System

  UBS’s rating system compares individual stock predicted returns (FSR) with baseline market returns (MRA). If FSR exceeds MRA by more than 6%, it's considered a buy; if below by more than 6%, a sell; otherwise, neutral. Here, FSR is 9.2%, MRA is 8.9%, resulting in a neutral classification.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pfizer (PFE.US)

  Direct subject of the report, rated neutral

  Strengths

  Strong Q1 beats expectations; robust core product lineup (Eliquis, Ibrance, Padcev et al.) shows compelling growth momentum; Tafamidis settlement boosts revenue visibility past 2029; ~6.6% dividend yield offers attractive shareholder returns; numerous upcoming catalysts

  Weaknesses

  Sharp decline in Comirnaty sales; facing >$150B patent expiration gap post-2028; market adopts cautious tone toward long-term growth; margin pressure from lagging/failing high-margin products

  Risks

  Pipeline failures (gene therapy, mRNA flu vaccine, oral GLP-1); slowdown in existing product growth (Comirnaty, Ibrance, Xeljanz, Xtandi, Eliquis); pricing pressures; profitability erosion from delayed/high-margin product setbacks; industry-wide risks from pricing reforms and enhanced PBM bargaining power

Key data

• Q1 Total Revenue144.51 Billion USDExceeds consensus of 138.4B USD, up 5.4% YoY
• Q1 Reported EPS0.75 USDAbove consensus of 0.72 USD, down 18.2% YoY
• Comirnaty (COVID-19 Vaccine) Q1 Revenue2.32 Billion USDSignificantly below consensus of 4.37B USD, down 58.9% YoY
• Eliquis Q1 Revenue21.66 Billion USDAbove consensus of 19.09B USD, up 12.6% YoY
• Padcev Q1 Revenue5.91 Billion USDAbove consensus of 5.33B USD, up 38.7% YoY
• 2026 Revenue Guidance595-625 Billion USDUnchanged
• 2026 Adjusted Diluted EPS Guidance2.80-3.00 USDUnchanged
• UBS 2026E EPS Forecast2.93 USDSlightly below consensus of 2.96 USD
• 12-Month Target Price27.00 USDBased on one-year forward P/E, supported by DCF; current price is 26.30 USD

Impact & implications

The report suggests that the Tafamidis settlement, extending Vyndamax/Vyndaqel exclusivity until 2031, provides crucial backing for Pfizer’s goal of achieving high-single-digit revenue growth post-2029 by improving the repairability and visibility of long-term income. Nevertheless, with over $150B in patent expirations looming after 2028, the market retains a watchful stance. Investors may continue to adopt conservative views on post-2029 growth until clinical data conclusively demonstrates the pipeline's ability to offset these losses. Recent agreements, such as the government pricing pact and reduced tariff uncertainties, have slightly improved overall operating conditions. Future pivotal data readouts, especially in antibody-drug conjugates (ADCs) and GLP-1 therapies, are key catalysts likely to validate pipeline potential and shift investor sentiment.

Risks

• Upside Risks: Better-than-expected Comirnaty performance; stronger Paxlovid commercialization; successful pipeline outcomes (mRNA flu vaccine, gene therapy, oral GLP-1); exceptional global execution; disciplined cost management leading to faster-than-expected margin expansion
• Downside Risks: Pipeline disappointments (gene therapy, mRNA flu vaccine, oral GLP-1); stagnation in key marketed products (Comirnaty, Ibrance, Xeljanz, Xtandi, Eliquis); intensified pricing pressures across portfolios; margin compression from declining high-margin products
• Industry Risks: Uncertainty in rebate structure changes; stricter drug pricing regulations impacting key markets; increasing consolidation among managed care organizations and PBMs enhancing negotiating leverage

What to watch

• Data readout from Sèv B6A ADC in second-line non-small cell lung cancer (2L NSCLC)
• MTSR obesity data: Complete VESPER-3 study data on monthly GLP-1 regimens, plus phase II GLP-1+amylin combination data
• Second-half readout of EZH2 prostate cancer Phase III data
• Insights from ASCO presentations relevant to PD-1×VEGF competitor data affecting Pfizer’s Phase III projects
• Progress on identifying which pipeline assets will replace >$150B in lost revenue from post-2028 patent expirations